Vivanza Biosciences Ltd
Vivanza Biosciences Ltd (VIVANZA) last reported results for the quarter ended Jun 2026, with sales of ₹9.29 crore and net profit of ₹0.15 crore. The stock last traded at ₹1.69, a market capitalisation of ₹6.76 crore, on a P/E of 14.7. Over the past 52 weeks the stock has ranged between ₹1.52 and ₹2.72. Figures are as of 6 Oct 2026 and are not real time.
Vivanza Biosciences Ltd share price and key metrics
- Current price
- ₹1.69
- Market cap
- ₹6.76 cr
- Stock P/E
- 14.7
- Book value
- ₹1.09
- ROE
- 9.38%
- ROCE
- 6.11%
- Dividend yield
- 0.00%
- 52w high / low
- 2.72/1.52
Metrics as of 6 Oct 2026. Not real time.
Track Vivanza Biosciences Ltd
Cruxal reads every Vivanza Biosciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Vivanza Biosciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- 64%
- 3 Years
- 87%
- TTM
- 735%
- 10 Years
- 24%
- 5 Years
- 37%
- 3 Years
- -13%
- TTM
- 154%
- 10 Years
- -16%
- 5 Years
- -36%
- 3 Years
- -46%
- 1 Year
- -18%
- 10 Years
- 2%
- 5 Years
- 6%
- 3 Years
- 2%
- Last Year
- 9%
Vivanza Biosciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹9.29 cr, up 3.9% from ₹8.94 cr a year earlier. Net profit was ₹0.15 cr, up 66.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 1.5 | 0.48 | 8.94 | 55.36 | 45.25 | 6.36 | 9.29 |
| Expenses | 2.89 | 1.37 | 1.44 | 8.79 | 54.75 | 45.04 | 6.59 | 9.36 |
| Operating profit | 0.11 | 0.13 | -0.96 | 0.15 | 0.61 | 0.21 | -0.23 | -0.07 |
| OPM % | 3.67% | 8.67% | -200.00% | 1.68% | 1.10% | 0.46% | -3.62% | -0.75% |
| Other income | 0 | 0.01 | 0.05 | 0.02 | 0.01 | 0.08 | 0.01 | 0.37 |
| Interest | 0.09 | 0.09 | 0.08 | 0.08 | 0.05 | 0.09 | 0.07 | 0.11 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 |
| Profit before tax | 0.02 | 0.05 | -0.99 | 0.09 | 0.57 | 0.2 | -0.3 | 0.18 |
| Tax % | 0.00% | 0.00% | 1.01% | 0.00% | 0.00% | 0.00% | 50.00% | 22.22% |
| Net profit | 0.02 | 0.04 | -1 | 0.09 | 0.56 | 0.2 | -0.45 | 0.15 |
| EPS (₹) | 0.00 | 0.01 | -0.25 | 0.02 | 0.14 | 0.05 | -0.11 | 0.04 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Vivanza Biosciences Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 6 | 3 | 10 | 10 | 10 | 18 | 28 | 7 | 116 | 116 |
| Operating profit | -0 | 1 | -0 | -0 | 0 | -0 | 1 | 1 | -0 | 1 | 1 |
| OPM % | -9% | 9% | -0.8% | -3.6% | 0.9% | -0.6% | 3.8% | 3.9% | -4.9% | 0.6% | 0.5% |
| Net profit | -0 | 0 | -0 | -0 | 0 | 0 | 1 | 1 | -1 | 0 | 0 |
| EPS (₹) | -0.08 | 0.05 | -0.11 | -0.05 | 0.02 | 0.08 | 0.15 | 0.14 | -0.17 | 0.10 | 0.12 |
TTM is the trailing twelve months to the most recent quarter.
Vivanza Biosciences Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves | -0 | -0 | -1 | -1 | -1 | -1 | 0 | 1 | -0 | 0 |
| Borrowings | 1 | 1 | 1 | 0 | 0 | 6 | 8 | 5 | 9 | 10 |
| Other liabilities | 3 | 5 | 6 | 9 | 5 | 7 | 10 | 10 | 4 | 8 |
| Total liabilities | 7 | 10 | 11 | 12 | 8 | 16 | 22 | 20 | 16 | 22 |
| Fixed assets | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 5 | 8 | 9 | 10 | 6 | 13 | 20 | 17 | 14 | 20 |
| Total assets | 7 | 10 | 11 | 12 | 8 | 16 | 22 | 20 | 16 | 22 |
As reported by the company. Total assets equal total liabilities by construction.
Vivanza Biosciences Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -2 | -0 | 1 | 3 | -3 | 2 | -1 | 2 | -2 | -3 |
| Cash from investing | 2 | 0 | 0 | 0 | -0 | 0 | 0 | -0 | -0 | -0 |
| Cash from financing | 0 | -1 | -1 | -3 | 3 | -2 | 1 | -2 | 2 | 3 |
| Net cash flow | 0 | -1 | -0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 |
| Free cash flow | -2 | -0 | 1 | 3 | -3 | 2 | -1 | 2 | -3 | -3 |
| CFO / operating profit | 668% | -15% | -4,300% | -876% | -3,367% | -4,117% | -124% | 203% | 692% | -328% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Vivanza Biosciences Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | -10% | 13% | -0% | 6% | 17% | 12% | 11% | 10% | -3% | 6% |
| Debtor days | 267 | 287 | 782 | 250 | 231 | 275 | 256 | 151 | 398 | 39 |
| Inventory days | 215 | 150 | 309 | 38 | 26 | 92 | 55 | 28 | 121 | 11 |
| Days payable | 304 | 319 | 878 | 319 | 154 | 207 | 211 | 116 | 140 | 23 |
| Cash conversion cycle | 178 | 118 | 213 | -32 | 103 | 160 | 99 | 64 | 379 | 27 |
| Working capital days | 332 | 237 | 469 | 109 | 104 | 103 | 50 | 44 | 154 | 7 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Vivanza Biosciences Ltd shareholding pattern
Promoters held 20.02% at Jun 2026, broadly unchanged since Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 39.86% | 20.02% | 20.02% | 20.02% | 20.02% | 20.02% | 20.02% | 20.02% |
| Public | 60.13% | 79.98% | 79.98% | 79.98% | 79.98% | 79.98% | 79.98% | 79.98% |
| No. of shareholders | 16,701 | 20,635 | 20,833 | 20,458 | 20,170 | 19,822 | 19,461 | 19,254 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Vivanza Biosciences Ltd corporate filings
- Vivanza Biosciences Ltd clarifies non-applicability of Regulation 32 statements as no additional funds raisedCompany Updatelow impact
Cruxal's analysis: The company states that it has not raised any further funds, hence the statements of…
Read the full analysis - Compliance certificate under reg. 74(5) of SEBI (DP) Regulation 2018, received from Purva Share Registry (I) Pvt Ltd and Share Transfer Agent (RTA) of the company for the Quarter ended ....Company Updatelow impact
- Closure of Trading Window for the Quarter and half year ending 30th September, 2026.Insider Trading / SASTlow impact
- Vivanza Biosciences Limited Announces Voting Results of 44th Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Vivanza Biosciences Limited has disclosed the voting results for its 44th Annual General…
Read the full analysis - Vivanza Biosciences Limited issues corrigendum regarding AGM e-voting service providerAGM/EGMlow impact
Cruxal's analysis: Vivanza Biosciences Limited has issued a corrigendum to its previously filed 44th Annual…
Read the full analysis - Vivanza Biosciences Limited concludes 44th Annual General Meeting; seeks shareholder approval for increased borrowing and related party transactionsAGM/EGMlow impact
Cruxal's analysis: Vivanza Biosciences Limited has formally concluded its 44th Annual General Meeting held…
Read the full analysis - Vivanza Biosciences Limited announces 44th Annual General Meeting scheduled for September 11, 2026Company Updatelow impact
Cruxal's analysis: Vivanza Biosciences Limited has issued a formal notice for its 44th Annual General…
Read the full analysis - Vivanza Biosciences Ltd releases Annual Report for FY 2025-2026Otherslow impact
Cruxal's analysis: Vivanza Biosciences Ltd has filed its Annual Report for the financial year 2025-2026. The…
Read the full analysis - Vivanza Biosciences Limited Announces 44th AGM and Reports Significant Financial Turnaround for FY 2025-26AGM/EGMhigh impact
Cruxal's analysis: Vivanza Biosciences Limited has scheduled its 44th Annual General Meeting for September…
Read the full analysis - Vivanza Biosciences Limited Announces Board Approval for 44th AGM and Proposals to Increase Borrowing and Investment LimitsBoard Meetinglow impact
Cruxal's analysis: Vivanza Biosciences Limited has announced the scheduling of its 44th Annual General…
Read the full analysis - Vivanza Biosciences Limited schedules Board Meeting for August 17, 2026, to approve FY26 financials and AGM agendaBoard Meetinglow impact
Cruxal's analysis: Vivanza Biosciences Limited has issued an intimation for a Board Meeting scheduled on…
Read the full analysis - Vivanza Biosciences Ltd confirms non-applicability of Regulation 32 regarding fund utilizationCompany Updatelow impact
Cruxal's analysis: Vivanza Biosciences Ltd has formally declared that the Statement of Deviation or…
Read the full analysis - Vivanza Biosciences Limited Reports Unaudited Financial Results for Quarter Ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Vivanza Biosciences Limited has formally intimated the publication of its unaudited…
Read the full analysis - Vivanza Biosciences Reports Q1 FY27 Financial Results with Consolidated Net Profit of 0.15 CroreBoard Meetinghigh impact
Cruxal's analysis: Vivanza Biosciences Limited has released its unaudited financial results for the quarter…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.